Continuing Pharmacy Education / CE Master List / Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety – RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Patient Safety: Anticoagulation Stewardship: Identifying Key Data, Avoiding Errors, and Enhancing Safety – RECORDED WEBINAR

The Arthur E. Schwarting Symposium is an educational conference focused on pharmacy practice for pharmacists in many settings.

This year's sympoisum had an overall topic of information overload.

Learning Objectives

Differentiate high-priority, practice-changing information from less relevant or conflicting data after reviewing the anticoagulation guidelines, literature and clinical updates.
Recognize common anticoagulation-related errors in pharmacy practice and implement strategies to minimize patient safety risks
Identify red flag situations in anticoagulation management that pose patient safety risks.
Determine the appropriate guidelines or evidence-based resources to guide clinical decision-making and referrals

Activity Release Dates

Released:  April 24, 2025
Expires:  April 24, 2028

Course Fee

$17 Pharmacist

ACPE UAN Codes

0009-0000-25-029-H05-P

Session Code

25RS29-CBA96

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-25-029-H05-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

 Youseff Besada, PharmD, BCPS, BCPP
Assistant Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

  • Youssef Bessada doesn't have any relationships with ineligible companies.

 

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test Pharmacist

1. Which of the following BEST represents a high-priority takeaway from current guideline recommendations for DOAC use in atrial fibrillation?
a) DOACs are preferred over warfarin in all patients with AF
b) Apixaban is the only DOAC that does not require renal dosing adjustments
c) DOACs should not be used in patients with mechanical heart valves

2. A 68-year-old male with nonvalvular atrial fibrillation (weight 60 kg, age 78) and SCr 1.4 mg/dL is started on apixaban. Which of the following would be considered a dosing error?
a) apixaban 5 mg BID
b) apixaban 2.5 mg BID
c) warfarin with a target INR of 2–3

3. A 55-year-old female patient with atrial fibrillation (weight 75 kg, SCr 1.6 mg/dL) and recent MI has been taking apixaban 5 mg BID, clopidogrel 75 mg daily, aspirin 81 mg daily, and pantoprazole 40 mg for the past 7 months. Which of the following should be considered a red flag that would prompt pharmacist stewardship at this point?
a) Use of aspirin in combination with DAPT
b) Use of clopidogrel in a patient with CAD
c) Use of apixaban for stroke prevention at the incorrect dose

4. You are managing a patient with cirrhosis (Child-Pugh Class B) who requires anticoagulation for VTE. Which of the following is the most appropriate course of action?
a) Prescribe rivaroxaban using its complete prescribing information recommendation
b) Refer to hepatology/hematology to discuss bleeding risk and treatment alternatives
c) Use warfarin because it’s always the safest anticoagulant in liver disease

5. A patient newly started on warfarin reports they “just stopped eating leafy greens” to be safe. What is the best pharmacist action?
a) Encourage the patient to continue avoiding all vitamin K-containing foods
b) Educate that consistent vitamin K intake is more important than avoiding it
c) Schedule weekly INR checks and adjust the warfarin dose aggressively